- Home
- YMM vs EXEL Comparison
YMM vs EXEL Comparison
Compare YMM & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMM | EXEL |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0B | 11.1B |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | YMM | EXEL |
|---|---|---|
| Price | $11.75 | $40.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 24 |
| Target Price | $12.67 | ★ $44.73 |
| AVG Volume (30 Days) | ★ 7.4M | 2.5M |
| Earning Date | 11-17-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.63% | N/A |
| EPS Growth | 29.34 | ★ 53.55 |
| EPS | 0.53 | ★ 2.38 |
| Revenue | $1,751,813,549.00 | ★ $2,288,218,000.00 |
| Revenue This Year | $11.64 | $9.84 |
| Revenue Next Year | $8.97 | $11.92 |
| P/E Ratio | $22.51 | ★ $17.20 |
| Revenue Growth | ★ 19.09 | 9.93 |
| 52 Week Low | $9.45 | $31.90 |
| 52 Week High | $14.07 | $49.62 |
Technical Indicators
Market Signals| Indicator | YMM | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.14 | 43.05 |
| Support Level | $11.34 | $43.00 |
| Resistance Level | $11.68 | $44.79 |
| Average True Range (ATR) | 0.26 | 1.15 |
| MACD | 0.13 | -0.45 |
| Stochastic Oscillator | 80.06 | 3.65 |
Price Performance
Historical ComparisonAbout YMM Full Truck Alliance Co. Ltd. (each representing 20)
Full Truck Alliance Co Ltd, through its subsidiaries, provides comprehensive services for shippers and truckers through its mobile and website platforms. Its principal operations are in the People's Republic of China. The group derives its revenues principally from shippers and trucker's use of its platforms in connection with freight matching services and value-added services.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.